The standard lipid panel your doctor orders – total cholesterol, LDL-C, HDL-C, triglycerides, and sometimes VLDL – reports how much cholesterol is carried in different lipoproteins. Prevention raises a related but different question: how many particles are carrying it? This page explains that gap in detail; for the short overview of three tests worth asking about, see Three Blood Tests Worth Asking Your Clinician About for Prevention.
The most common misunderstanding is what LDL-C actually measures. LDL-C estimates the mass of cholesterol carried inside LDL particles. It doesn’t count the particles themselves. ApoB – apolipoprotein B – tracks the number of atherogenic particles, because each LDL, VLDL, chylomicron, and lipoprotein(a) particle contains one molecule of apoB.[1] A narrative review explains why that matters: cholesterol can only enter the artery wall inside apoB particles, so the number of particles trapped in the wall, not just the cholesterol per particle, determines how much cholesterol is deposited.[1]
Think of it this way: LDL-C is like measuring the total weight of all the cars on a highway. ApoB is like counting the cars themselves. If car manufacturers start making lighter cars, the total weight goes down while the number of cars stays the same – and it’s the number of cars, not their weight, that sets the traffic. The cholesterol inside a particle is cargo. How many particles there are determines how many get stuck in artery walls.
Two people can have the same LDL-C and different particle counts, because the amount of cholesterol per particle varies, with smaller particles carrying less.[2] In the Multi-Ethnic Study of Atherosclerosis, which followed 6,814 people free of cardiovascular disease for about 5.5 years, LDL-C and LDL particle number (measured by NMR) disagreed in many people. Among those whose values disagreed, only the particle number was associated with later cardiovascular events (hazard ratio 1.45 per standard deviation, versus 1.07 for LDL-C).[2] That study measured LDL particle number, not apoB. In a separate meta-analysis of 12 reports covering 233,455 people, apoB was the most potent marker of cardiovascular risk, LDL-C the least, and non-HDL-C fell in between.[3]
For many people LDL-C and apoB tell the same story. The mismatch matters most when they disagree, and a standard panel can’t show you that.
What should a prevention-focused lipid panel include? Bettering Me suggests asking your clinician about ApoB, Lp(a) (checked once), non-HDL cholesterol, triglycerides, and HDL-C. Non-HDL cholesterol (total cholesterol minus HDL-C) is a practical stand-in when apoB isn’t available, because it reflects the cholesterol in all the apoB-containing particles. In the meta-analysis above it predicted risk better than LDL-C but not as well as apoB, so it is a stand-in, not an equal.[3]
Lipoprotein(a) – Lp(a) – is worth checking once. Its heritability exceeds 90%,[5] and its concentrations are not much influenced by diet or physical activity.[4] A 2022 European Atherosclerosis Society consensus statement recommends measuring Lp(a) at least once in adults. It suggests Lp(a) above 50 mg/dL (125 nmol/L) as a level that rules in higher risk, below 30 mg/dL (75 nmol/L) as a level that rules it out, and 30-50 mg/dL as a grey zone, and notes that assays cannot strictly report in molar units, so results are otherwise reported in mg/dL.[5] For someone with a high Lp(a), the panel recommends early, intensive management of other risk factors, with LDL-C, blood pressure, glucose, and lifestyle factors managed according to baseline risk and Lp(a) level.[5] A high reading doesn’t mean you’re doomed. It means a conversation with your clinician about your overall risk.
What are the apoB targets? The 2019 ESC/EAS dyslipidaemia guidelines list apoB secondary goals of below 65, 80, and 100 mg/dL for people at very high, high, and moderate cardiovascular risk, respectively. They list non-HDL-C secondary goals of below 85, 100, and 130 mg/dL for the same three groups.[6] Your risk category depends on your overall risk, which your clinician assesses. These are treatment goals within a guideline, not a way to diagnose yourself from one number, so ask which one applies to you.
Counterpoint: isn’t LDL-C good enough for most people? The ESC/EAS guidelines set LDL-C goals for each risk category and describe their apoB and non-HDL-C goals as secondary, so LDL-C remains central to clinical practice.[6] For many people the two will agree. The case for adding apoB is strongest for people whose LDL-C and particle number are likely to disagree, and your clinician can tell you whether that applies. Cost depends on your lab and insurance, so check before ordering.
The standard panel isn’t useless. It is incomplete for prevention purposes. Knowing your LDL-C without knowing your apoB is like knowing your speed without knowing whether you’re on a straight road or a winding mountain pass. Speed is useful. Context changes how you read it.
Practical guidance for your next lab visit. When your doctor orders a “lipid panel,” you typically get total cholesterol, LDL-C, HDL-C, triglycerides, and sometimes VLDL. To add apoB, ask for “apolipoprotein B.” To add Lp(a), ask for “lipoprotein (a).” Some labs bundle these as an “advanced lipid panel” or “cardiovascular risk panel,” so ask what a bundle includes. If apoB isn’t available, non-HDL cholesterol (total minus HDL) is a stand-in, and most standard panels already report it. Take your results to your clinician, who can place them in the context of your history.
References
↑︎ Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA Cardiol. 2019;4(12):1287-1295. DOI: https://doi.org/10.1001/jamacardio.2019.3780
↑︎ Otvos JD, Mora S, Shalaurova I, et al. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol. 2011;5(2):105-113. DOI: https://doi.org/10.1016/j.jacl.2011.02.001
↑︎ Sniderman AD, Williams K, Contois JH, et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes. 2011;4(3):337-345. DOI: https://doi.org/10.1161/CIRCOUTCOMES.110.959247
↑︎ Kronenberg F. Human genetics and the causal role of lipoprotein(a) for various diseases. Cardiovasc Drugs Ther. 2016;30(1):87-100. DOI: https://doi.org/10.1007/s10557-016-6648-3
↑︎ Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925-3946. DOI: https://doi.org/10.1093/eurheartj/ehac361
↑︎ Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-188 (apoB and non-HDL-C secondary goals: p. 132 and Table 7, p. 133; LDL-C goals: Table 7, p. 133). DOI: https://doi.org/10.1093/eurheartj/ehz455
Kurt Greiner
Kurt is a digital strategist and IT professional blending emerging technology with practical application to help businesses and individuals streamline their digital presence. His current work focuses on the intersection of intentional living and technological resilience, exploring how individuals can leverage modern tools to navigate the second half of life with purpose.
Leave a Reply